Experienced in Fanconi Anemia

Dr. Courtney Dinardo

Hematology
University Of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 428, 
Houston, TX 
Clinical Trials:Currently Recruiting for 5 Trials
Offers Telehealth
Experienced in Fanconi Anemia
University Of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 428, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Courtney Dinardo is a Hematologist in Houston, Texas. Dr. Dinardo is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 561 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Fanconi Anemia.

Specialties
Hematology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 428, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
Enrollment Status: Recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Drugs: Ivosidenib, Liposomal Daunorubicin, Liposomal Cytarabine
Study Phase: Phase 2
Phase 1b/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib
Phase 1b/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drugs: Decitabine, Cedazuridine, Enasidenib, Ivosidenib, Venetoclax
Study Phase: Phase 1/Phase 2
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Ivosidenib, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim, Venetoclax
Study Phase: Phase 1/Phase 2
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: August 13, 2025
Intervention Type: Other, Drug
Study Drugs: Azacitidine, Enasidenib
Study Phase: Phase 2
Phase Ib/II Study of Omacetaxine and Venetoclax for Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase Ib/II Study of Omacetaxine and Venetoclax for Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Enrollment Status: Terminated
Publish Date: November 03, 2025
Intervention Type: Drug
Study Drugs: Omacetaxine Mepesuccinate, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Biological
Study Drug: IO-202
Study Phase: Phase 1
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Glutaminase Inhibitor CB-839
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
Evaluating the Effect of a Digital Coaching Program on Self-Efficacy and Patient Reported Outcomes of Individuals With Acute and Chronic Leukemia
Evaluating the Effect of a Digital Coaching Program on Self-Efficacy and Patient Reported Outcomes of Individuals With Acute and Chronic Leukemia
Enrollment Status: Completed
Publish Date: September 18, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: CB-5339
Study Phase: Phase 1
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drugs: Cytarabine, Milademetan Tosylate, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1b/2a Open-label, Multi-center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects With AML
A Phase 1b/2a Open-label, Multi-center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects With AML
Enrollment Status: Terminated
Publish Date: August 08, 2022
Intervention Type: Drug
Study Drugs: Brequinar, Ribavirin
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

554 Total Publications

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Journal: Leukemia
Published: December 10, 2025
Similar Doctors
Advanced in Fanconi Anemia
Dr. Alison Bertuch
Hematology | Oncology
Advanced in Fanconi Anemia
Dr. Alison Bertuch
Hematology | Oncology

Office

1102 Bates Ave, 
Houston, TX 
 (0.4 miles away)
832-822-4240
Languages Spoken:
English
See accepted insurances

Alison Bertuch is a Hematologist and an Oncologist in Houston, Texas. Dr. Bertuch is rated as a Distinguished provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Aplastic Anemia, Dyskeratosis Congenita, Shwachman-Diamond Syndrome, Acquired Amegakaryocytic Thrombocytopenia, and Bone Marrow Transplant.

Experienced in Fanconi Anemia
Dr. Lawrence Rice
Hematology
Experienced in Fanconi Anemia
Dr. Lawrence Rice
Hematology

Houston Methodist Academic Medicine Specialists

6550 Fannin St Ste 1101, 
Houston, TX 
 (0.6 miles away)
713-903-2837
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lawrence Rice is a Hematologist in Houston, Texas. Dr. Rice is rated as a Distinguished provider by MediFind in the treatment of Fanconi Anemia. His top areas of expertise are Thrombocytopenia, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Rice is currently accepting new patients.

Experienced in Fanconi Anemia
Dr. Nidra Rodriguez
Hematology | Oncology
Experienced in Fanconi Anemia
Dr. Nidra Rodriguez
Hematology | Oncology

UT Health Science Center-Pediatric Pulmonary

6410 Fannin St Ste 500, 
Houston, TX 
 (0.3 miles away)
832-325-7111
Languages Spoken:
English
See accepted insurances

Nidra Rodriguez is a Hematologist and an Oncologist in Houston, Texas. Dr. Rodriguez is rated as an Experienced provider by MediFind in the treatment of Fanconi Anemia. Her top areas of expertise are Fanconi Anemia, Hemophilia A, Ataxia-Pancytopenia Syndrome, and Shwachman-Diamond Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dinardo's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 12 Distinguished Conditions
View All 10 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile